Respiratory Syncytial Virus: A Prioritized or Neglected Target?

• Nair H , NokesJD, GessnerBDet al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545–1555 (2010).
   PubMed Web of Science ®Google Scholar
• Rudan I , Boschi-PintoC, BiloglavZ, MulhollandK, CampbellH. Epidemiology and etiology of childhood pneumonia.Bull. World Health Organ.86(5), 408–416 (2008).
   PubMed Web of Science ®Google Scholar
• Simoes EAF . Respiratory syncytial virus infection.Lancet354(9181), 847–852 (1999).
   PubMed Web of Science ®Google Scholar
• Sigurs N , GustafssonPM, BjarnasonRet al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Cri. Care Med. 171(2), 137–141 (2005).
   PubMed Web of Science ®Google Scholar
• Simoes EA , GroothuisJR, Carbonell-EstranyXet al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151(1), 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Hall CB , WeinbergGA, IwaneMKet al. The burden of respiratory syncytial virus in young children. N. Engl. J. Med. 360(6), 588–598 (2009).
   PubMed Web of Science ®Google Scholar
• Madhi SA , LevineOS, HajjehR, MansoorOD, CherianT. Vaccines to prevent pneumonia and improve child survival.Bull. World Health Organ.86(5), 365–372 (2008).
   PubMed Web of Science ®Google Scholar
• Murata Y , FalseyAR. Respiratory syncytial virus infection in adults.Antivir. Ther.12(4), 659–670 (2007).
   PubMed Web of Science ®Google Scholar
• Falsey AR , HennesseyPA, FormicaMA, CoxC, WalshEE. Respiratory syncytial virus infection in elderly and high-risk adults.N. Engl. J. Med.352(17), 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson WW , ShayDK, WeintraubEet al. Mortality associated with influenza and respiratory syncytial virus in the United States. J. Am. Med. Assoc. 289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Morris SK , DzolganovskiB, BeyeneJ, SungL. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.BMC Infect. Dis.5(9), 106 (2009).
   Google Scholar
• Carbonell-Estrany X , SimõesEA, DaganRet al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125(1), e35–51 (2010).
   PubMed Web of Science ®Google Scholar
• Young D . FDA: MedImmune’s Rezield has 3x allergic reactions as Synagis.BioWorld Today21(104), 1–5 (2010).
   Google Scholar
• Murata Y . Respiratory syncytial virus vaccine development.Clin. Lab. Med.29(4), 725–739 (2009).
   PubMed Web of Science ®Google Scholar
• Haas MJ . Besieging RSV.SciBX2(1), 1–3 (2009).
   Google Scholar
• Nokes JD , CanePA. New strategies for control of respiratory syncytial virus infection.Curr. Opin. Infect. Dis.21(6), 639–643 (2008).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ , MitchellRH, ChanockRM, ShvedoffRA, StewartCE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.Am. J. Epidemiol.89(4), 405–421 (1969).
   PubMed Web of Science ®Google Scholar
• Kim HW , CancholaJG, BrandtCDet al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Neilson KA , YunisEJ. Demonstration of respiratory syncytial virus in an autopsy series.Pediatr. Pathol.10(4), 491–502 (1990).
   PubMedGoogle Scholar
• Delgado MF , CovielloS, MonsalvoACet al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15(1), 34–41 (2009).
   PubMed Web of Science ®Google Scholar
• Bueno SM , GonzálezPA, PachecoRet al. Host immunity during RSV pathogenesis. Int. Immunopharmacol. 8(10), 1320–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Welliver TP , GarofaloRP, HosakoteYet al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195(8), 1126–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Devincenzo J , Lambkin-WilliamsR, WilkinsonTet al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci. USA 107(19), 8800–8805 (2010).
   PubMed Web of Science ®Google Scholar
• Bonfanti JF , RoymansD. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.Curr. Opin. Drug Dev.12(4), 479–487 (2009).
   PubMedGoogle Scholar
• Olszewska W , OpenshawP. Emerging drugs for respiratory syncytial virus infection.Expert Opin. Emerg. Drugs14(2), 207–217 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman J , AbbottE, AlberDGet al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51(9), 3346–3353 (2007).
   PubMed Web of Science ®Google Scholar
• Lamb RA , JardetzkyTS. Structural basis of viral invasion: lessons from paramyxovirus F.Curr. Opin. Struct. Biol.17(4), 427–436 (2007).
   PubMed Web of Science ®Google Scholar
• Roymans D , De BondtHL, ArnoultEet al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl Acad. Sci. USA107(1), 308–313 (2010).
   PubMed Web of Science ®Google Scholar
• Cianci C , LangleyDR, DischinoDDet al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl Acad. Sci. USA 101(42), 15046–15051 (2004).
   PubMed Web of Science ®Google Scholar
• Legg JP , HussainIR, WarnerJA, JohnstonSL, WarnerJO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis.Am. J. Respir. Crit. Care Med.168(6), 633–639 (2003).
   PubMed Web of Science ®Google Scholar
• Aung S , RutiglianoJA, GrahamBS. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease.J. Virol.75(20), 9918–9924 (2001).
   PubMed Web of Science ®Google Scholar
• Welliver RC . The immune response to respiratory syncytial virus infection: friend or foe?.Clinic. Rev. Allerg. Immunol.34(2), 163–173 (2008).
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP . A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: how real infants suffer.J. Infect. Dis.195(8), 1084–1086 (2007).
   PubMed Web of Science ®Google Scholar
• Buckingham SC , JafriHS, BushAJet al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J. Infect. Dis. 185(9), 1222–1228 (2002).
   PubMed Web of Science ®Google Scholar
• Ermers MJJ , RoversMM, van Woensel JB et al. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomized double blind placebo controlled trial. BMJ338, b897 (2009).
   PubMedGoogle Scholar
• DeVincenzo JP , El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis.191(11), 1861–1868 (2005).
   PubMed Web of Science ®Google Scholar
• Buckingham SC , BushA, DeVincenzoJP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants.Pediatr. Infect. Dis. J.19(2), 113–117 (2000).
   PubMed Web of Science ®Google Scholar
• Hall CB . Respiratory syncytial virus in young children.Lancet375(9725), 1500–1502 (2010).
   PubMed Web of Science ®Google Scholar

Websites

• Keeping the promise: a forward-looking review to promote an agreed action agenda to achieve the Millennium Development Goals by 2015. United Nations, New York, NY, USA (2010). www.un.org/millenniumgoals
   Google Scholar
• Global action plan for prevention and control of pneumonia (GAPP). WHO-Unicef, Geneva, Switzerland (2009). http://whqlibdoc.who.int/hq/2009/WHO_FCH_CAH_NCH_09.04_eng.pdf
   Google Scholar
• Clinical Trials. http://clinicaltrials.gov
   Google Scholar